Epidemiology of primary myelofibrosis (PMF), essential thrombocythemia (ET), and polycythemia vera (PV) in the European Union (EU)

被引：0
|
作者：
Mehta, J. [1 ]
Le-Ruyet, O. [2 ]
Fryzek, J. [3 ]
Iqbal, S. U. [1 ]
Mesa, R. [4 ]
机构：
[1] Sanofi Aventis, Evidence & Value Dev, Cambridge, MA USA
[2] Sanofi Aventis, Evidence & Value Dev, Chilly Mazarin, France
[3] Epidstat Inst, Ann Arbor, MI USA
[4] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1489
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [21] Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia
    Johansson, P
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (03): : 171 - 173
  • [22] A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis
    Verstovsek, Srdan
    Savona, Michael R.
    Mesa, Ruben A.
    Oh, Stephen
    Dong, Hua
    Thai, Dung
    Gotlib, Jason
    BLOOD, 2015, 126 (23)
  • [23] Analysis of the Impact and Burden of Illness of Polycythemia Vera (PV) and Essential Thrombocythemia (ET) in the US
    Mehta, Jyotsna
    Wang, Hongwei
    Iqbal, Usman
    Mesa, Ruben A.
    BLOOD, 2012, 120 (21)
  • [24] Usefulness of spontaeous colony formation for diagnosis of polycythemia vera (PV) and essential thrombocythemia (ET)
    Scalzulli, PR
    Morelli, A
    Nobile, M
    DArena, G
    Perla, G
    Carotenuto, M
    Musto, P
    BLOOD, 1996, 88 (10) : 385 - 385
  • [25] A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Datoguia, Tarcila Santos
    Goncalves, Giulliana A. R.
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [26] Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Puga, Renato D.
    Alves Paiva, Raquel de Melo
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [27] Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post - Polycythemia, Vera Myelofibrosis (PPV - MF), and Post Essential Thrombocythemia Myelofibrosis (PET - MF)
    Vargas, Pablo
    Ovilla, Roberto
    Alvarado, Martha
    Lopez, Manuel
    Hurtado Monroy, Rafael
    Carlos Solis, Juan
    Limon, Alejandro
    Agreda, Gladys
    Silva, Salvador
    Julio Kassack, Juan
    Zavala, Saida
    Aguilar, Carlos
    Baez, Enrique
    Barrera, Esperanza
    Osuna, Antonio
    Morales, Javier
    Herrera, Aquileo
    BLOOD, 2012, 120 (21)
  • [28] Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
    Mora, Barbara
    Giorgino, Toni
    Guglielmelli, Paola
    Rumi, Elisa
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami
    Gotlib, Jason
    Kiladjian, Jean Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Barraco, Daniela
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Vannucchi, Alessandro Maria
    Passamonti, Francesco
    LEUKEMIA RESEARCH, 2018, 69 : 100 - 102
  • [29] THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H.
    Pardanani, A.
    Thomas, D.
    Cortes, J.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Fridman, J.
    Tefferi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 179 - 179
  • [30] Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
    Ogasawara, Ken
    Zhou, Simon
    Krishna, Gopal
    Palmisano, Maria
    Li, Yan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 891 - 898
12345